A provision buried in the fiscal bill passed earlier this month gives Amgen, the world's largest biotechnology firm, more time to sell a lucrative kidney dialysis drug without price restraints.No big surprise, we already knew the bill was larded with giveaways, but the NYT provides a nice look into the flawed process, which all starts with a small army of lobbyists. Read the whole thing.
Sunday, 20 January 2013
Larded by Lobbyists: More from the Fiscal Cliff
From the NYT today, Fiscal Footnote: Big Senate Gift to Drug Maker:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment